Delving into the Latest Updates on Autologous adipose derived stem cells(Makerere University) with Synapse

Overview

Basic Info

Drug Type

Stem cell therapy

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Skin and Musculoskeletal Diseases

Active Indication-

Inactive Indication

Keloid

Originator Organization

Makerere University

Active Organization-

Inactive Organization

Makerere University

License Organization-

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Keloids are the most common disfiguring skin disorder affecting colored population with a prevalence of upto 16%.
Autologous adipose derived stem cells have been found to have potential therapeutic benefits however limited clinical trials have compared there role to standard therapy.
This is a pilot study that is intended to evaluate the feasibility of conducting this clinical trial comparing adipose derived stromal vascular fraction to Triamcinolone in keloid treatment. The full clinical trial is already registered under the clinical trial number NCT04391621.
The objective of this Pilot is to evaluate the feasibility of conducting a full study on the same topic.

Start Date01 Mar 2021

Sponsor / Collaborator

Makerere University

IRCT2016111427865N2

/ CompletedPhase 1/2IIT

Evaluation of the safety and feasibility of intra-arterial injection of autologous stem cells derived from adipose tissue in stroke patients.

Start Date21 Dec 2016

Sponsor / Collaborator-

100 Clinical Results associated with Autologous adipose derived stem cells(Makerere University)

Login to view more data

100 Translational Medicine associated with Autologous adipose derived stem cells(Makerere University)

Login to view more data